Thrombolysis for acute stroke under antiplatelet therapy: Safe enough to be beneficial?

Nature Clinical Practice Neurology

Volumn 4, Issue 9, 2008, Pages 474-475

  Hacke, Werner ^a   Lichy, Christoph ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; TISSUE PLASMINOGEN ACTIVATOR;

AGING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHRONIC DRUG ADMINISTRATION; COMORBIDITY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; EXPERIMENTAL DESIGN; HUMAN; INCIDENCE; MONOTHERAPY; NOTE; OFF LABEL DRUG USE; PATIENT SAFETY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SAMPLE SIZE; SYMPTOMATOLOGY; VASCULAR DISEASE;

EID: 52049088262     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0867     Document Type: Note

References (12)

1. Uyttenboogaart M et al. (2008) Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol 65: 607-611
2. Wahlgren N et al. (2007) Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): An observational study. Lancet 369: 275-282
3. Hacke W et al. (2004) Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363:768-774
4. The European Stroke Organisation (ESO) writing committee (2008) Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25: 457-507
5. Adams HP et al. (2007)Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Stroke 38: 1655-1711
6. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333: 1581-1587
7. Sanossian N et al. (2006) Premorbid antiplatelet use and ischemic stroke outcomes. Neurology 66: 319-323
8. Wolf PA et al. (1991) Probability of stroke: A risk profile from the Framingham Study. Stroke 22: 312-318
9. Schmulling S et al. (2003) Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. Cerebrovasc Dis 16: 183-190
10. Tanne D et al. (2002) Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: The Multicenter rt-PA Stroke Survey. Circulation 105: 1679-1685
11. The NINDS t-PA Stroke Study Group (1997) Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 28: 2109-2118
12. Larrue V et al. (2001) Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 32 438-441